Abstract 216P
Background
A previous pan-cancer single-cell study on the tumor microenvironment (TME), particularly tumor-infiltrating lymphocytes (TILs), highlighted both the heterogeneity and dynamics of various T cell subtypes. However, the spatial heterogeneity of TILs in breast cancer has not been extensively studied. We aimed to investigate the spatial heterogeneity of the TME using spatial transcriptomics.
Methods
We retrospectively collected FFPE samples from five breast cancer cases (2 triple-negative breast cancer [TNBC] with high TILs, 2 TNBC with low TILs, 1 hormone receptor-positive[HR+] breast cancer with TIL high TILs) and performed the Visium Spatial Gene Expression method (10x Genomics). Subsequently, using public TILs single-cell data from a pan-cancer study, we predicted and annotated cell types in each Visium spot (single cell deconvolution). We studied the distribution of T cell subtypes across three layers at 3mm intervals from the most peripheral to the central direction of the tumor.
Results
The distribution of 24 CD4+ subtypes and 17 CD8+ subtypes was examined. In all five cases, the CD8.c.12.Tex.CXCL13 subtype showed a statistically significant increase in cell numbers at the tumor center compared to the periphery. The CD4.c20.Treg.TNFRSF9 subtype displayed a similar trend, with higher cell counts in the tumor center and lower counts in the periphery. Conversely, the CD8.c10.Trm.ZNF683 subtype, a key subtype in the previous pan-cancer study, exhibited varying distribution patterns between cases.
Conclusions
TILs in breast cancer consist of diverse subtypes. Numerical heterogeneity was observed among T cell subtypes, along with spatial heterogeneity between the tumor’s central and peripheral regions. Furthermore, heterogeneity was evident between individual tumors. However, some consistent distribution patterns, such as the CD8.c.12.Tex.CXCL13 population, were also observed across cases. Further studies are needed to determine the clinical significance of this spatial heterogeneity.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract